7 terminated. 7 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Terminated 7 |
| Phase 1 | 3 | Terminated 3 |
Follow poly ICLC: new trials by email Literature Review of poly ICLC trials Research Report on poly ICLC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase II Trial of Poly-ICLC for Low-Grade Gliomas Poly ICLC - NF1, Low-grade Glioma | Phase 2 | Terminated | University of Alabama at Birmingham | 3 | 2022-02-08 | 2025-03-21 |
| Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Atezolizumab, DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Guadecitabine - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 9 | 2017-11-08 | 2026-10-20 |
| A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma Combination of varlilumab and ipilimumab, Cohort A: varlilumab & ipilimumab; Cohort B: varlilumab, ipilimumab, CDX-1401 & poly-ICLC - Unresectable Stage III or Stage IV Melanoma | Phase 1 / Phase 2 | Terminated | Celldex Therapeutics | 9 | 2015-04-01 | 2017-04-07 |
| Phase I/II: Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs Vaccine (autologous dendritic cells), Decitabine and Hiltonol - Gliomas, Medulloblastoma | Phase 1 / Phase 2 | Terminated | University of Louisville | 1 | 2015-04-01 | 2018-05-04 |
| Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC) Poly-ICLC - Melanoma, Squamous Cell Carcinoma of the Head and Neck | Phase 2 | Terminated | Nina Bhardwaj | 8 | 2013-11-01 | 2018-01-23 |
| Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC MAGE-A3 ASCI injections without Poly IC:LC, MAGE-A3 ASCI injections with Poly IC:LC - Melanoma | Phase 2 | Terminated | H. Lee Moffitt Cancer Center and Research Institute | 14 | 2011-10-11 | 2019-12-20 |
| Biological Therapy and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme poly ICLC - Brain and Central Nervous System Tumors | Phase 2 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 31 | 2002-10-23 | 2018-07-18 |
Melanoma (3) · Breast Neoplasms (1) · Central Nervous System Neoplasms (1) · Fallopian Tube Neoplasms (1) · Glioblastoma (1) · Glioma (1) · Gliosarcoma (1) · Medulloblastoma (1) · Neuroectodermal Tumors, Primitive (1) · Ovarian Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1)
Celldex Therapeutics (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · National Cancer Institute (NCI) (1) · Nina Bhardwaj (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · University of Alabama at Birmingham (1) · University of Louisville (1)
United States (7)
Juliette Southworth, BS, CCRP (1) · Kenneth G Lucas, MD (1) · Kunle Odunsi (1) · Michael Prados, MD (1) · Nikhil Khushalani, M.D. (1) · Nina Bhardwaj, MD, PhD (1)
PMID 18797818, PMID 24801836, PMID 34171339
P30CA016056 (1)